已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

阵发性夜间血红蛋白尿 医学 血红蛋白 胃肠病学 血红蛋白尿 临床终点 临床试验 内科学 贫血
作者
Régis Peffault de Latour,Alexander Röth,Austin Kulasekararaj,Bing Han,Phillip Scheinberg,Jaroslaw P. Maciejewski,Yasutaka Ueda,Carlos M. de Castro,Eros Di Bona,Rong Fu,Zhang Li,Morag Griffin,Saskia Langemeijer,Jens Panse,Hubert Schrezenmeier,Wilma Barcellini,Vitor AQ Mauad,Philippe Schafhausen,Suzanne Tavitian,Eloise Beggiato
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:390 (11): 994-1008 被引量:131
标识
DOI:10.1056/nejmoa2308695
摘要

BACKGROUND: Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors. Iptacopan, a first-in-class oral factor B inhibitor, has been shown to improve hemoglobin levels in these patients. METHODS: In two phase 3 trials, we assessed iptacopan monotherapy over a 24-week period in patients with hemoglobin levels of less than 10 g per deciliter. In the first, anti-C5-treated patients were randomly assigned to switch to iptacopan or to continue anti-C5 therapy. In the second, single-group trial, patients who had not received complement inhibitors and who had lactate dehydrogenase (LDH) levels more than 1.5 times the upper limit of the normal range received iptacopan. The two primary end points in the first trial were an increase in the hemoglobin level of at least 2 g per deciliter from baseline and a hemoglobin level of at least 12 g per deciliter, each without red-cell transfusion; the primary end point for the second trial was an increase in hemoglobin level of at least 2 g per deciliter from baseline without red-cell transfusion. RESULTS: In the first trial, 51 of the 60 patients who received iptacopan had an increase in the hemoglobin level of at least 2 g per deciliter from baseline, and 42 had a hemoglobin level of at least 12 g per deciliter, each without transfusion; none of the 35 anti-C5-treated patients attained the end-point levels. In the second trial, 31 of 33 patients had an increase in the hemoglobin level of at least 2 g per deciliter from baseline without red-cell transfusion. In the first trial, 59 of the 62 patients who received iptacopan and 14 of the 35 anti-C5-treated patients did not require or receive transfusion; in the second trial, no patients required or received transfusion. Treatment with iptacopan increased hemoglobin levels, reduced fatigue, reduced reticulocyte and bilirubin levels, and resulted in mean LDH levels that were less than 1.5 times the upper limit of the normal range. Headache was the most frequent adverse event with iptacopan. CONCLUSIONS: Iptacopan treatment improved hematologic and clinical outcomes in anti-C5-treated patients with persistent anemia - in whom iptacopan showed superiority to anti-C5 therapy - and in patients who had not received complement inhibitors. (Funded by Novartis; APPLY-PNH ClinicalTrials.gov number, NCT04558918; APPOINT-PNH ClinicalTrials.gov number, NCT04820530.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏的应助被xxdwyd采纳,获得10
刚刚
我吃吃吃吃吃吃完成签到 ,获得积分10
刚刚
1秒前
1秒前
daomaihu发布了新的文献求助100
2秒前
mycoplasma完成签到 ,获得积分10
2秒前
万万发布了新的文献求助10
3秒前
jmc发布了新的文献求助10
3秒前
林深完成签到 ,获得积分10
5秒前
yuanyu发布了新的文献求助10
5秒前
雪山大地发布了新的文献求助10
6秒前
陈预立发布了新的文献求助10
7秒前
思源的应助被鳗鱼雪莲采纳,获得10
8秒前
杏仁和巧克力完成签到 ,获得积分10
8秒前
11秒前
11秒前
SciGPT的应助被温某人采纳,获得10
11秒前
由道罡完成签到 ,获得积分10
12秒前
14秒前
乐乐的应助被橙橙采纳,获得10
15秒前
RRGrel完成签到,获得积分10
16秒前
数据线完成签到 ,获得积分10
17秒前
LIXIA完成签到 ,获得积分10
17秒前
17秒前
认真青曼完成签到,获得积分20
18秒前
夏色弥深完成签到 ,获得积分10
18秒前
鳗鱼雪莲发布了新的文献求助10
19秒前
英姑的应助被愉快的伊采纳,获得10
19秒前
pp完成签到 ,获得积分10
19秒前
19秒前
20秒前
呼延水云完成签到,获得积分10
21秒前
读书崽完成签到 ,获得积分10
21秒前
songkoro完成签到,获得积分10
21秒前
yu123123发布了新的文献求助10
22秒前
景三完成签到 ,获得积分10
22秒前
Luuuuu发布了新的文献求助10
22秒前
23秒前
笙笙的应助被T0Yu采纳,获得10
23秒前
苏哈托发布了新的文献求助10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172605
求助须知:如何正确求助?哪些是违规求助? 9565323
关于积分的说明 21778953
捐赠科研通 7764352
什么是DOI,文献DOI怎么找? 3431411
关于科研通互助平台的介绍 2555301
邀请新用户注册赠送积分活动 2476394